Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 6000
- Registration Number
- NCT00092703
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092768
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2904
- Registration Number
- NCT00092586
An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1104
- Registration Number
- NCT00092664
Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 655
- Registration Number
- NCT00092716
MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1902
- Registration Number
- NCT00092690
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 410
- Registration Number
- NCT00092599
An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 450
- Registration Number
- NCT00092638
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 372
- Registration Number
- NCT00092612
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 442
- Registration Number
- NCT00092625
© Copyright 2024. All Rights Reserved by MedPath